The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30503
Abstract: Oncogenic mutations of BRAF lead to constitutive ERK activity that supports melanoma cell growth and survival. While Ca2+ signaling is a well‐known regulator of tumor progression, the crosstalk between Ca2+ signaling and the Ras‐BRAF‐MEK‐ERK pathway… read more here.
Keywords: melanoma; braf mutant; mutant melanoma; pmca4b ... See more keywords
FAM129B‐dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Carcinogenesis"
DOI: 10.1002/mc.23295
Abstract: Incidence of melanoma continues to rise in the United States with ~100,000 new cases diagnosed in 2019. While the 5‐year survival rate of melanoma is 99% when localized, the rate of survival drops to 22.5%… read more here.
Keywords: melanoma; mutant melanoma; braf; melanoma cells ... See more keywords
Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.3c00094
Abstract: Mutations in NRAS promote tumorigenesis and drug resistance. As this protein is often considered an undruggable target, it is urgent to develop novel strategies to suppress NRAS for anticancer therapy. Recent reports indicated that a… read more here.
Keywords: discovery clinically; mutant melanoma; nras mutant; nras repressor ... See more keywords
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-27643-3
Abstract: Despite major advances in targeted melanoma therapies, drug resistance limits their efficacy. Long noncoding RNAs (lncRNAs) are transcriptome elements that do not encode proteins but are important regulatory molecules. LncRNAs have been implicated in cancer… read more here.
Keywords: nras mutant; mutant melanoma; mapk pathway; modulates mapk ... See more keywords
Clinical trial results show promise of targeting autophagy BRAF mutant melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Autophagy"
DOI: 10.1080/15548627.2022.2038899
Abstract: ABSTRACT Macroautophagy/autophagy is a resistance mechanism to targeted therapy in BRAF mutant cancers. Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations. Here we highlight… read more here.
Keywords: melanoma; trial; braf mutant; mutant melanoma ... See more keywords
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
Sign Up to like & getrecommendations! Published in 2023 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001500
Abstract: Reactive oxygen species (ROS) levels are elevated after acquisition of resistance to v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors including dabrafenib and MEK inhibitors such as trametinib in BRAF-mutant melanoma. To circumvent toxicity… read more here.
Keywords: tdr; ridr 103; braf; inhibitor ... See more keywords
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004095
Abstract: Background Patients with BRAF-mutant and wild-type melanoma have different response rates to immune checkpoint blockade therapy. However, the reasons for this remain unknown. To address this issue, we investigated the precise immune composition resulting from… read more here.
Keywords: braf; melanoma; mutant melanoma; treatment naive ... See more keywords
BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-0098
Abstract: Purpose: NRAS mutations in malignant melanoma are associated with aggressive disease requiring rapid antitumor intervention, but there is no approved targeted therapy for this subset of patients. In clinical trials, the MEK inhibitor (MEKi) binimetinib… read more here.
Keywords: melanoma; nras mutant; mutant melanoma; braf ... See more keywords
Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1795
Abstract: Mutations in BRAF outside of the 600 codons (BRAF non- V600) occur across cancer types, including in 3% to 5% of melanomas. The optimal treatment strategies are not clear but based on preclinical studies could… read more here.
Keywords: braf mutant; class matters; sensitivity braf; mutant melanoma ... See more keywords
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3382
Abstract: Abstract Purpose: Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg twice daily and trametinib 2 mg every day… read more here.
Keywords: melanoma; brafv600 mutant; trial; rate ... See more keywords
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3872
Abstract: Abstract Purpose: Enhanced MAPK pathway signaling and cell-cycle checkpoint dysregulation are frequent in NRAS-mutant melanoma and, as such, the regimen of the MEK inhibitor binimetinib and the selective CDK4/6 inhibitor ribociclib is a rational combination.… read more here.
Keywords: patients nras; phase; combination; mutant melanoma ... See more keywords